Skip to main content

Table 1 Overview of the assay performance of anti-SmD1 and anti-SmD3 ELISAs determined in independent studies

From: Effect of dsDNA binding to SmD-derived peptides on clinical accuracy in the diagnosis of systemic lupus erythematosus

Disease/control group SmD1 ELISA SmD3 ELISA
  Previous studies Present study   Present study, panel I
  Riemekasten and colleagues, 1998 [15] Jaekel and colleagues, 2001 [20] Panel I (25 units) Panel I (100 units) Panel III (25 units) Panel III (100 units) Mahler and colleagues, 2005 [14]  
Systemic lupus erythematosus (n) 167 111 48 48 100 100 176 48
Controls (n) 372 144 99 99 100 100 449 99
Primary Sjögren syndrome (n) 15 10 - - 7 7 24 -
Mixed connective tissue disease (n) 23 13 16 16 7 7 26 16
Rheumatoid arthritis (n) 28 10 50 50 22 22 86 50
Miscellaneous (n) 73 21 15 15 5 5 21 15
Undifferentiated connective tissue disease (n) - 22 - - - - - -
Scleroderma (n) 20 11 17 17 18 18 26 17
Normal human donor (n) 105 50 - - 20 20 192 -
Polymyositis scleroderma overlap syndrome (n) - 7 11 11 6 6 - 11
Human immunodeficiency virus (n) 88 - - - 5 5 - -
Hepatitis B virus (n) 20 - - - 5 5 - -
Hepatitis C virus (n) - - - - 5 5 30 -
Cytomagalovirus (n) - - - - - - 22 -
Epstein–Barr virus (n) - - - - - - 25 -
Sensitivity (%) 70 36 45.8 12.5 47 21 15.9 12.5
Specificity (%) 91.7 97.2 77.8 100 84 100 99.8 100